{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:30:09Z","timestamp":1774575009080,"version":"3.50.1"},"reference-count":39,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T00:00:00Z","timestamp":1473897600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec id=\"S1092852916000444_abs1\" sec-type=\"general\"><jats:title>Objective<\/jats:title><jats:p>This analysis of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study (NCT01157351) compared outcomes after administration of once-monthly paliperidone palmitate (PP) vs conventional oral antipsychotics (COAs) or atypical oral antipsychotics (AOAs).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852916000444_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>PRIDE was a 15-month study of 444 individuals with schizophrenia and a history of incarceration. They were randomly assigned to PP or to 1 of 7 commonly prescribed OAs. Primary endpoint was time to first treatment failure (TF). Event-free probabilities were estimated using the Kaplan\u2013Meier method; treatment group differences (PP vs COAs, PP vs AOAs, and PP vs oral paliperidone\/risperidone) were assessed using a log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression models. No adjustment was made for multiplicity.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852916000444_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Compared with PP, risk for first TF was 34% higher with COAs (HR: 1.34; 95% CI: 0.80\u20132.25), 41% higher with AOAs (HR: 1.41; 95% CI: 1.06\u20131.88), and 39% higher with paliperidone\/risperidone (HR: 1.39; 95% CI: 0.97\u20131.99). Incidences of extrapyramidal symptom\u2013related adverse events (AEs) were 45.7%, 13.7%, and 10.6% in the COA, AOA, and oral paliperidone\/risperidone groups vs 23.9% in the PP group. Incidences of prolactin-related AEs were 5.7%, 3.8%, and 3.5% vs 23.5%, and incidences of \u22657% weight increase were 11.4%, 14.9%, and 16.0% vs 32.4%.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852916000444_abs4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>Results suggest a lower risk of TF but a higher rate of some AEs after treatment with PP vs COAs, AOAs, and paliperidone\/risperidone. Deselection of specific OAs and low patient-compliance rates with OAs likely biased the safety results.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852916000444","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T07:34:47Z","timestamp":1473924887000},"page":"466-477","source":"Crossref","is-referenced-by-count":15,"title":["Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia"],"prefix":"10.1017","volume":"21","author":[{"given":"Edward","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Lynn","family":"Starr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Alphs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"S1092852916000444_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2011.02.001"},{"key":"S1092852916000444_ref34","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20060"},{"key":"S1092852916000444_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2004.07.003"},{"key":"S1092852916000444_ref25","first-page":"375","article-title":"Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia","volume":"8","author":"Sliwa","year":"2012","journal-title":"Neuropsychiatr Dis Treat"},{"key":"S1092852916000444_ref8","first-page":"23","article-title":"A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia","volume":"7","author":"Macfadden","year":"2010","journal-title":"Psychiatry"},{"key":"S1092852916000444_ref18","first-page":"695","article-title":"Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability\u2014a review","volume":"9","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"S1092852916000444_ref3","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181dd3103"},{"key":"S1092852916000444_ref9","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs150"},{"key":"S1092852916000444_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.05.014"},{"key":"S1092852916000444_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2014.11.006"},{"key":"S1092852916000444_ref39","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-12-22"},{"key":"S1092852916000444_ref17","doi-asserted-by":"publisher","DOI":"10.1177\/2045125311413006"},{"key":"S1092852916000444_ref37","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2013.811984"},{"key":"S1092852916000444_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.11.008"},{"key":"S1092852916000444_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01223-9"},{"key":"S1092852916000444_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.08.015"},{"key":"S1092852916000444_ref10","unstructured":"Janssen Pharmaceuticals, Inc. INVEGAR SUSTENNAR (paliperidone palmitate) extended-release injectable suspension, for intramuscular use. 2012. Titusville, NJ: Janssen Pharmaceuticals, Inc."},{"key":"S1092852916000444_ref33","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.137"},{"key":"S1092852916000444_ref31","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"S1092852916000444_ref28","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S77778"},{"key":"S1092852916000444_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.10.026"},{"key":"S1092852916000444_ref35","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"S1092852916000444_ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"S1092852916000444_ref26","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001076"},{"key":"S1092852916000444_ref7","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-946703"},{"key":"S1092852916000444_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60995-8"},{"key":"S1092852916000444_ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-12-26"},{"key":"S1092852916000444_ref30","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"S1092852916000444_ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-79"},{"key":"S1092852916000444_ref14","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.79"},{"key":"S1092852916000444_ref1","unstructured":"National Institute of Mental Health. Schizophrenia [Web page]. Washington, DC: National Institute of Mental Health; 2014. http:\/\/www.nimh.nih.gov\/statistics\/1SCHIZ.shtml. Accessed May 1, 2014."},{"key":"S1092852916000444_ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12493"},{"key":"S1092852916000444_ref15","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-10-12"},{"key":"S1092852916000444_ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00982.x"},{"key":"S1092852916000444_ref27","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08965"},{"key":"S1092852916000444_ref22","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S36438"},{"key":"S1092852916000444_ref29","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09584"},{"key":"S1092852916000444_ref12","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.FUBO.022213"},{"key":"S1092852916000444_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.08.014"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852916000444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T10:12:26Z","timestamp":1706004746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852916000444\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1092852916000444"],"URL":"https:\/\/doi.org\/10.1017\/s1092852916000444","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,15]]}}}